32: The Future of Glycoengineering: Trends Unveiled w/ Thomas Rexer - Part 2

Discover the hurdles and breakthroughs in glycoengineering, including the high costs of activated sugars. Thomas Rexer, CTO of eversyn, a spin-off of the Max Planck Institute Magdeburg, unveils eversyn's multi-step biocatalysis process, designed to significantly drive down costs and make in vitro glycoengineering more accessible on a large scale. Key Insights: Uncover the power of multistep biocatalysis in driving down costs and making in vitro glycoengineering more accessible. Bridge the Gap between academia and industry in glycoengineering and thus ensure a smoother integration of groundbreaking glycoengineering technologies into the industrial landscape. Gain valuable insights into the challenges and triumphs of transitioning from pure science to entrepreneurship, offering aspiring scientists a roadmap to navigate the unknown. Connect with Thomas Rexer: LinkedIn: https://www.linkedin.com/in/thomas-rexer Website: www.eversyn.de Next Step: Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com Support the show